Key result
Losartan was safe and well tolerated after acute myocardial infarction, decreasing end-systolic volume and increasing left ventricular ejection fraction.
RCT (n=201)
Answers are grounded in this paper and cite their sources.
Supports losartan as safe ARB alternative post-MI; extends ARB evidence to ventricular remodeling in acute infarction.
AIM OF STUDY: Angiotensin-converting enzyme (ACE) inhibitors prolong life, lower the progression of heart failure, and decrease the need for hospitalizations in patients after myocardial infarctions. It is still unclear whether these effects could also be achieved by blocking the angiotensin II (ATII) type 1 receptor. METHODS AND RESULTS: We randomized 201 patients with acute myocardial infarction treated with either direct angioplasty, thrombolysis, or heparin alone to the ACE inhibitor captopril or the ATII antagonist losartan. The primary endpoints were safety, tolerability, and left ventricular parameters. The patients were followed for at least 15 days. The incidence of severe adverse events was similar in both groups, although cough presented less often in the losartan group. Captopril failed to prevent an increase in end-diastolic volume and did not influence left ventricular end-systolic volume. This effect led to an increase in the left ventricular ejection fraction (P<0. 001) without a change in wall-motion index. Losartan did not affect end-diastolic volume but decreased end-systolic volume (P<0.001), resulting in a significant increase in left ventricular ejection fraction (P<0.001) and a decrease in wall-motion index (P<0.001). CONCLUSION: This study suggests that losartan is safe and well tolerated in patients after myocardial infarction. ATII antagonists seem to have a more pronounced effect on left ventricular remodeling than ACE inhibitors.
No takes yet. Share an insight, caveat, or question.
Špinar et al. (2000) conducted an RCT in Acute myocardial infarction (n=201). Losartan vs. Captopril was evaluated on Safety, tolerability, and left ventricular parameters (p=<0.001). Losartan was safe and well tolerated after acute myocardial infarction, decreasing end-systolic volume and increasing left ventricular ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: